A recent meta-analysis proposed that circulating interleukin 6 (IL-6) and C-Reactive Protein (CRP) could potentially serve as robust biomarkers for predicting poor prognosis in patients with glioma (Feng et al., 2019). This evidence concerns the gene CRP and central nervous system cancer.